- Home
- CLPR vs SCLX Comparison
CLPR vs SCLX Comparison
Compare CLPR & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- SCLX
- Stock Information
- Founded
- CLPR 2015
- SCLX 2011
- Country
- CLPR United States
- SCLX United States
- Employees
- CLPR 171
- SCLX N/A
- Industry
- CLPR Real Estate Investment Trusts
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- CLPR Real Estate
- SCLX Health Care
- Exchange
- CLPR Nasdaq
- SCLX Nasdaq
- Market Cap
- CLPR 57.8M
- SCLX 51.3M
- IPO Year
- CLPR 2017
- SCLX N/A
- Fundamental
- Price
- CLPR $3.67
- SCLX $6.02
- Analyst Decision
- CLPR Sell
- SCLX Strong Buy
- Analyst Count
- CLPR 2
- SCLX 4
- Target Price
- CLPR N/A
- SCLX $11.33
- AVG Volume (30 Days)
- CLPR 212.1K
- SCLX 68.9K
- Earning Date
- CLPR 05-06-2025
- SCLX 05-12-2025
- Dividend Yield
- CLPR 10.30%
- SCLX N/A
- EPS Growth
- CLPR N/A
- SCLX N/A
- EPS
- CLPR N/A
- SCLX N/A
- Revenue
- CLPR $148,775,000.00
- SCLX $56,590,000.00
- Revenue This Year
- CLPR N/A
- SCLX $115.30
- Revenue Next Year
- CLPR N/A
- SCLX $73.33
- P/E Ratio
- CLPR N/A
- SCLX N/A
- Revenue Growth
- CLPR 7.65
- SCLX 21.07
- 52 Week Low
- CLPR $3.38
- SCLX $5.80
- 52 Week High
- CLPR $7.12
- SCLX $80.50
- Technical
- Relative Strength Index (RSI)
- CLPR 44.08
- SCLX 30.63
- Support Level
- CLPR $3.60
- SCLX $6.13
- Resistance Level
- CLPR $3.82
- SCLX $7.64
- Average True Range (ATR)
- CLPR 0.23
- SCLX 1.42
- MACD
- CLPR 0.01
- SCLX -0.21
- Stochastic Oscillator
- CLPR 41.59
- SCLX 3.80
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.